Conivaptan: promise of treatment in heart failure

被引：7

作者：

Hoque, Mohammad Z. ^{[1
]}

Arumugham, Pradeep ^{[1
]}

Huda, Nazmul ^{[1
]}

Verma, Nitin ^{[1
]}

Afiniwala, Mitul ^{[1
]}

Karia, Darshak H. ^{[1
]}

机构：

[1] Albert Einstein Med Ctr, Philadelphia, PA 19141 USA

来源：

EXPERT OPINION ON PHARMACOTHERAPY | 2009年 / 10卷 / 13期

关键词：

conivaptan; heart failure; hyponatremia; vasopressin antagonism; LEFT-VENTRICULAR DYSFUNCTION; VASOPRESSIN RECEPTOR ANTAGONIST; CONVERTING-ENZYME INHIBITORS; PREDICTING MORTALITY; SYSTOLIC FUNCTION; DOUBLE-BLIND; CANDESARTAN; MORBIDITY; EFFICACY; SAFETY;

D O I：

10.1517/14656560903173237

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Conivaptan, the first vasopressin receptor antagonist approved by the FDA, is available for the treatment of hyponatremia in euvolemic and hypervolemic patients. The renin-angiotensin-aldosterone system is activated in heart failure (HF) causing clinical worsening. Arginine vasopressin levels are also elevated in HE Conivaptan is an effective and FDA approved for the treatment of euvolemic and hypervolemic hyponatremia and may offer an extra treatment option in HIF by targeting V-1a and V-2 receptors. In this article we review the physiology, preclinical studies as well as the human clinical studies on the use of conivaptan and its potential and promise in the treatment of HF.

引用

页码：2161 / 2169

页数：9

共 38 条

[1]

[Anonymous], HEART DIS STROK STAT

[2] Vasopressin receptor antagonists: potential indications and clinical results [J].

Arai, Yukinori ;

Fujimori, Akira ;

Sudoh, Katsumi ;

Sasamata, Masao .

CURRENT OPINION IN PHARMACOLOGY, 2007, 7 (02) :124-129

[3] Pharmacokinetic and pharmacodynamic effects of YM087, a combined V1/V2 vasopressin receptor antagonist in normal subjects [J].

Burnier, M ;

Fricker, AF ;

Hayoz, D ;

Nussberger, J ;

Brunner, HR .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 55 (09) :633-637

[4]

Clair MJ, 2000, J PHARMACOL EXP THER, V293, P852

[5]

*CLIN GOV REG, SAF EFF CON HYP PAT

[6]

*CLIN GOV REG, DIUR REN EFF VAPR AD

[7] A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure [J].

Cohn, JN ;

Tognoni, G .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (23) :1667-1675

[8] Overview of acutely decompensated congestive heart failure (ADHF): A report from the ADHERE Registry [J].

Fonarow, GC .

HEART FAILURE REVIEWS, 2004, 9 (03) :179-185

[9] COMPARISON OF NEUROENDOCRINE ACTIVATION IN PATIENTS WITH LEFT-VENTRICULAR DYSFUNCTION WITH AND WITHOUT CONGESTIVE-HEART-FAILURE - A SUBSTUDY OF THE STUDIES OF LEFT-VENTRICULAR DYSFUNCTION (SOLVD) [J].

FRANCIS, GS ;

BENEDICT, C ;

JOHNSTONE, DE ;

KIRLIN, PC ;

NICKLAS, J ;

LIANG, CS ;

KUBO, SH ;

RUDINTORETSKY, E ;

YUSUF, S .

CIRCULATION, 1990, 82 (05) :1724-1729

[10] Rationale and study design for a multicenter, randomized, double-blind, placebo-controlled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure [J].

Gheorghiade, M ;

Gattis, WA ;

Barbagelata, A ;

Adams, KF ;

Elkayam, U ;

Orlandi, C ;

O'Connor, CM .

AMERICAN HEART JOURNAL, 2003, 145 (02) :S51-S54

← 1 2 3 4 →